SEC Comment Letter 0000000000-24-012527 to ANAPTYSBIO, INC (ANAB) (CIK 0001370053) (ANAB)
ANAPTYSBIO, INC (ANAB) (CIK 0001370053)
Date: Nov. 12, 2024 · CIK: 0001370053 · Accession: 0000000000-24-012527
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-283001
Letter
November 12, 2024 Daniel Faga Chief Executive Officer AnaptysBio, Inc. 10770 Wateridge Circle, Suite 210 San Diego, CA 92121 Re:AnaptysBio, Inc. Registration Statement on Form S-3 Filed November 5, 2024 File No. 333-283001 Dear Daniel Faga: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Ryan Mitteness
Show Raw Text
November 12, 2024
Daniel Faga
Chief Executive Officer
AnaptysBio, Inc.
10770 Wateridge Circle, Suite 210
San Diego, CA 92121
Re:AnaptysBio, Inc.
Registration Statement on Form S-3
Filed November 5, 2024
File No. 333-283001
Dear Daniel Faga:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Ryan Mitteness